Medicus Pharma Ltd.

Medicus Pharma Ltd. is a clinical-stage biotechnology and life sciences company focused on accelerating the development of novel and potentially disruptive therapeutic assets. The company's mission involves identifying, acquiring, and advancing de-risked clinical-stage assets through clinical development and commercialization, with the goal of delivering improved treatment outcomes. Medicus Pharma Ltd. is headquartered in West Conshohocken, Pennsylvania, United States.

The company's primary therapeutic assets include SkinJect™ and Teverelix®. SkinJect™ is a localized immuno-oncology product utilizing dissolvable microneedle arrays for the treatment of non-melanoma skin diseases, specifically basal cell carcinoma (BCC) and Gorlin Syndrome. This asset is currently undergoing Phase 2 clinical studies. Teverelix® is a next-generation GnRH antagonist being developed for hormone-driven conditions, such as cardiovascular high-risk advanced prostate cancer and acute urinary retention relapse (AURr) due to enlarged prostate, with potential applications also being explored in women's health for conditions like endometriosis and uterine fibroids.

Medicus Pharma Ltd. is publicly traded on NASDAQ under the ticker MDCX. Recent activities in April 2026 include the CEO meeting with lawmakers on Capitol Hill to advocate for Orphan Drug Designation for SkinJect® in Gorlin Syndrome, and the submission of an Orphan Drug Designation application for this indication. The company also presented new Phase 1 clinical data for Teverelix® at the American Association of Clinical Endocrinology Annual Meeting 2026. Dr. Raza Bokhari serves as the Executive Chairman and CEO, leading the company's efforts to advance its pipeline through Phase 2 proof-of-concept studies, aiming for subsequent licensing or strategic partnerships with established pharmaceutical companies.